A new innovation in its branch science made her appearance recently. It is a drug molecule invented with the help of it artificial intelligence (AI), from the British Newcomer company Exscientia and the Japanese pharmaceutical company Sumitomo Dainippon Pharma. This drug is to be used, initially in a trial, in machine learning for medicine. Specifically, the drug will be used to treat patients suffering from obsessive compulsive disorder (OCD). Typically and under normal circumstances h procedure It takes about five years for them to be available for testing. Nevertheless the process creation The drug created with the help of AI technology lasted only 12 months.
Exscientia CEO Andrew Hopkins described the new prototype drug as a "key milestone in drug discovery". At the same time in an interview with with the BBC said that until now AI technology has been used for diagnosis and analysis of diseases. data the patients. But this is the first time AI has been the key core of creating a drug.
This particular drug molecule, known as DSP-1181, was created using algorithms which have been obtained through various potential combinations of compounds, and have undergone controls against a large number parameters.
According to Professor Hopkins, it takes a long and meticulous process to find the right molecules and precisely create a drug. As for the algorithms, their magic is because they are unknowing, and therefore can be applied to any disease.
The company is already working for invention drug for the treatment of cancer and cardiovascular disease and aspires to prepare another drug molecule by the end of 2020 with the help of AI technology, which will be available for clinical trials.
Finally, the Managing Director of the Institute of Cancer Research, Paul Workman, who did not participate in the researchshe said excited with her discovery noting that use AI technology is designed to facilitate and speed up the process of generating more and more drugs.